Kennedy's Follow-On Biologics Revisions Add Anti-"Evergreening" Language
This article was originally published in The Pink Sheet Daily
Executive Summary
Restrictions are similar to those in Rep. Waxman's bill, but less specific.
You may also be interested in...
Follow-on Biologics Base Camp: Senate Has Four Rival Proposals
Brand biologics fare well in the amendments prepared for the HELP Committee mark-up, as even Sen. Brown offers at least seven years of exclusivity.
Follow-on Biologics Base Camp: Senate Has Four Rival Proposals
Brand biologics fare well in the amendments prepared for the HELP Committee mark-up, as even Sen. Brown offers at least seven years of exclusivity.
FOBs Must Follow The Senate’s Health Reform Pathway; Placeholder Is Key
The state of the congressional debate on follow-on biologics legislation is probably best expressed by the first line on the topic from the most prominent bill: "[Policy under discussion].